Geert Cauwenbergh, President & CEO at RXi Pharmaceuticals Corp (RXII), bought 10,000 shares at $0.69 ($7K) on 2017-02-08, disclosed to the SEC on 2017-02-08.
Open-market purchase of $7k RXII by President & CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| RXII | BUY | 2017-06-22 | $6K | — | Filing → |
| RXII | BUY | 2017-04-26 | $7K | — | Filing → |
| RXII | BUY | 2017-03-20 | $8K | — | Filing → |